泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

已收盘 05-08 16:08:16

27.050

+0.200

+0.74%

最高27.600	最低26.950	成交量127.75万
今开27.200	昨收26.850	日振幅2.42%
总市值233.97亿	流通市值33.27亿	总股本8.65亿
成交额3,484万	换手率1.04%	流通股本1.23亿
市净率1.06	ROE1.01%	每股收益0.50
52周最高58.800	52周最低22.300	市盈率53.67
股息0.32	股息收益率0.01	ROA1.80%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":27.05,"timestamp":1746691696017,"preClose":26.85,"halted":0,"volume":1277500,"delay":0,"floatShares":123000000,"shares":864948570,"eps":0.5040197212270052,"marketStatus":"已收盘","change":0.2,"latestTime":"05-08 16:08:16","open":27.2,"high":27.6,"low":26.95,"amount":34838342,"amplitude":0.024209,"askPrice":27.05,"askSize":1000,"bidPrice":27,"bidSize":11300,"shortable":3,"etf":0,"ttmEps":0.41739936737881883,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746754200000},"marketStatusCode":5,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":26.85,"dividendRate":0.01181,"openAndCloseTimeList":[[1746667800000,1746676800000],[1746680400000,1746691200000]],"volumeRatio":0.653519,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":45.97,"timestamp":1746687600000,"preClose":45.95,"halted":0,"volume":6886700,"delay":0,"premium":"-45.19"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2533971255","title":"人福医药最新公告：子公司宜昌人福血管紧张素Ⅱ注射液获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533971255","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533971255?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:11","pubTimestamp":1746695500,"startTime":"0","endTime":"0","summary":"人福医药(600079.SH)公告称，公司控股子公司宜昌人福药业有限责任公司收到国家药监局核准签发的血管紧张素Ⅱ注射液《药物临床试验批准通知书》。该药品为化学药品3类，用于成人感染性休克或其他分布性休克患者的升压治疗。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800023965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0070","03347","BK0185","600079","BK0188","BK0096","BK0012","BK1583","BK0239","BK1576","BK0028"],"gpt_icon":0},{"id":"2533239389","title":"北京免疫方舟医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533239389","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533239389?lang=zh_cn&edition=full","pubTime":"2025-05-08 14:06","pubTimestamp":1746684381,"startTime":"0","endTime":"0","summary":"5月8日，据CDE官网消息，北京免疫方舟医药科技有限公司联合申请药品“IMB071703注射液”，获得临床试验默示许可，受理号CXSL2500189。北京免疫方舟医药科技有限公司，成立于2017年，位于北京市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，北京免疫方舟医药科技有限公司参与招投标项目4次，知识产权方面有商标信息5条，专利信息19条，此外企业还拥有行政许可6个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/08140650218876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","09939","BK1576","BK1161","BK1515","BK1583","BK1141","03347","159938"],"gpt_icon":0},{"id":"2533933720","title":"中国生物科技服务(08037)附属将于第18届国际恶性淋巴瘤会议及第30届欧洲血液学年会上展示LY007细胞注射液I期研究临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533933720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533933720?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:24","pubTimestamp":1746624251,"startTime":"0","endTime":"0","summary":"LY007的临床成果亮点为填补CD20 CAR-T治疗空白。上海隆耀计划于国际恶性淋巴瘤会议与欧洲血液学年会平台，进一步推动LY007 的国际多中心临床研究，并探索与欧美机构的合作。在近一年时间内，上海隆耀LY007的I期临床研究成果在全球各大肿瘤与血液病学术年会上陆续发布，代表着 LY007在全球学术领域获得了认可及关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","08037","BK1583","BK1576","BK1219","BK1511"],"gpt_icon":0},{"id":"2533483987","title":"远大医药：全球创新放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请已获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533483987","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533483987?lang=zh_cn&edition=full","pubTime":"2025-05-07 20:24","pubTimestamp":1746620640,"startTime":"0","endTime":"0","summary":"格隆汇5月7日丨远大医药公告，集团用于治疗前列腺癌的全球创新放射性核素偶联药物TLX591 加入国际多中心III期临床试验的申请，近日已获得中国国家药品监督管理局正式受理，这是集团在核药抗肿瘤诊疗领域的重要研发进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507202633a4755f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507202633a4755f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","BK1141","BK1191","00512","03347"],"gpt_icon":0},{"id":"2533861509","title":"远大医药(00512)全球创新放射性核素偶联药物 TLX591 加入国际多中心 III 期临床试验的申请已获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533861509","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533861509?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:17","pubTimestamp":1746616646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 公布，该集团用于治疗前列腺癌的全球创新放射性核素偶联药物 TLX591 加入国际多中心 III 期临床试验的申请，近日已获得中华人民共和国国家药品监督管理局正式受理，这是集团在核药抗肿瘤诊疗领域的重要研发进展。此前，该集团用于诊断前列腺癌的全球创新 RDC 产品 TLX591-CDx 已于2023年8月在中国完成 III 期临床试验首例患者给药，并计划于今年二季度完成全部患者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1141","03347","BK4134","BK1583","III","BK1576","00512"],"gpt_icon":0},{"id":"2533608009","title":"微芯生物：西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608009?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:39","pubTimestamp":1746610767,"startTime":"0","endTime":"0","summary":"西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析，独立评审委员会评估结果显示：在经过广泛抗肿瘤免疫治疗后的总体人群中，西奥罗尼组与安慰剂组相比中位无进展生存期显著延长，降低疾病进展风险70%以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700027025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1583","03347","688321","BK1576","BK1141"],"gpt_icon":0},{"id":"2533677832","title":"卫信康(603676.SH)子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2533677832","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533677832?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:20","pubTimestamp":1746609610,"startTime":"0","endTime":"0","summary":"智通财经APP讯，卫信康(603676.SH)公告，近日，公司全资子公司内蒙古白医制药股份有限公司(简称“白医制药”)收到国家药品监督管理局(简称“国家药监局”)核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。据悉，本品是一种胶体性容量代用品，用于：1、相对或绝对低血容量及休克的治疗。2、预防低血压。预防脊髓或硬膜外麻醉后可能出现的低血压，预防手术期间可能出现的大量失血所致的低血压。3、与晶体溶液联合用药作为灌注液的成分参与体外循环过程(例如，心肺机)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","03347","BK1141","BK0191","BK1583","BK1576","603676"],"gpt_icon":0},{"id":"2533672426","title":"卫信康最新公告：子公司获得琥珀酰明胶注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2533672426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533672426?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:13","pubTimestamp":1746609190,"startTime":"0","endTime":"0","summary":"卫信康(603676.SH)公告称，公司全资子公司白医制药收到国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》，同意该药品开展临床试验。该药品是一种胶体性容量替代品，用于相对或绝对低血容量及休克的治疗等。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700025974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0191","BK1141","03347","BK0239","603676","BK1583"],"gpt_icon":0},{"id":"2533060645","title":"泰格医药05月07日主力净流出261.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533060645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533060645?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:15","pubTimestamp":1746605751,"startTime":"0","endTime":"0","summary":"05月07日, 泰格医药股价跌1.83%，报收26.85元，成交金额5118.6万元，换手率1.52%，振幅4.39%，量比1.06。泰格医药今日主力资金净流出261.8万元，上一交易日主力净流入293.4万元。该股近5个交易日上涨0.94%，主力资金累计净流出222.1万元；近20日主力资金累计净流出362.0万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171806a4752438&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171806a4752438&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1141","03347","BK1576"],"gpt_icon":0},{"id":"2533506338","title":"华东医药(000963.SZ)：注射用HDM2005临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506338","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533506338?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:21","pubTimestamp":1746523260,"startTime":"0","endTime":"0","summary":"华东医药发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，由中美华东申报的注射用HDM2005临床试验申请获得批准。注射用HDM2005在中国和美国的临床试验于2024年6月分别获得NMPA和美国食品药品监督管理局批准，适应症为晚期恶性肿瘤。2025年2月，HDM2005的套细胞淋巴瘤适应症获得美国FDA孤儿药资格认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK1141","BK0132","BK1583","03347","BK0175","BK0196","BK1576","LU2328871848.SGD","BK0187","LU1969619763.USD","BK0183","000963","BK0209"],"gpt_icon":0},{"id":"2533570853","title":"泰恩康：CKBA软膏白癜风适应症II期临床试验在今年4月底已完成全部受试者的用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2533570853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533570853?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:09","pubTimestamp":1746522586,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，公司在去年十月份发布了ckba白癜风II期临床完成全部受试者入组的公告，请问目前临床进展如何？预计什么时候公布临床结果？泰恩康回复：您好，CKBA软膏白癜风适应症II期临床试验在今年4月底已完成全部受试者的用药，预计将于今年7月公布II期临床试验结果。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050600023148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","03347","BK0250","301263","BK1141","BK1583"],"gpt_icon":0},{"id":"2533579335","title":"歌礼制药：欧洲肥胖症大会报告ASC47研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533579335","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533579335?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:43","pubTimestamp":1746520990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","BK1141","01672","01477","BK1191","BK1574","03347","BK1576","BK1583","BK1161"],"gpt_icon":0},{"id":"2533201599","title":"金十数据整理：每日港股市场要闻速递（5月6日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533201599","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533201599?lang=zh_cn&edition=full","pubTime":"2025-05-06 09:11","pubTimestamp":1746493895,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE0008369823.USD","BK4207","IE00B5MMRT66.SGD","000655","LU2236285917.USD","LU2357305700.SGD","03347","600276","LU0310800965.SGD","YANG","02380","LU1226288170.HKD","LU1989772840.SGD","BK1601","LU2539964713.USD","LU0072461881.USD","LU2023251221.USD","LU2125154935.USD","02888","LU0170899867.USD","LU0307460666.USD","STAN.UK","LU2347655156.SGD","LU0225284248.USD","BK4585","07226","IE0008368742.USD","BK1592","BK4581","LU1008478684.HKD","LU2148510915.USD","LU0149534421.HKD","01093","LU0162691827.USD","03143","BK0012","LU0971096721.USD","HSCEI","SG9999004220.SGD","02562","03939","01996","161631","LU0006306889.USD","LU2488822045.USD","LU0912757837.SGD","IE00BKVL7J92.USD","HSTECH","LU0321505868.SGD"],"gpt_icon":0},{"id":"2533058503","title":"桂林三金最新公告：控股孙公司BC006单抗注射液新增适应症获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533058503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533058503?lang=zh_cn&edition=full","pubTime":"2025-05-05 16:10","pubTimestamp":1746432623,"startTime":"0","endTime":"0","summary":"桂林三金(002275.SZ)公告称，公司控股孙公司宝船生物医药科技（上海）有限公司收到国家药品监督管理局核准签发的BC006单抗注射液的临床试验批件，同意本品开展用于特发性肺纤维化适应症的临床试验。该药品此前已获得晚期恶性肿瘤的临床试验批件，目前处于I期临床试验进行中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050500001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","03347","BK1583","BK1576","BK0028","BK0239","BK0060","002275","BK1141"],"gpt_icon":0},{"id":"2533303417","title":"桂林三金：控股孙公司BC006单抗注射液新增适应症获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533303417","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533303417?lang=zh_cn&edition=full","pubTime":"2025-05-05 16:07","pubTimestamp":1746432426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0188","399441","002275","BK1141","BK1583","BK1576","BK0028","BK0060","BK0239","03347","161726"],"gpt_icon":0},{"id":"2533035623","title":"桂林三金(002275.SZ)：BC006单抗注射液新增适应症获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533035623","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533035623?lang=zh_cn&edition=full","pubTime":"2025-05-05 15:57","pubTimestamp":1746431878,"startTime":"0","endTime":"0","summary":"桂林三金(002275.SZ)公告，公司控股孙公司宝船生物医药科技(上海)有限公司...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK0188","BK1141","03347","BK0028","BK1576","002275","BK0060","BK0239"],"gpt_icon":0},{"id":"2532819985","title":"石药集团：JMT202(重组全人源抗βKLOTHO单克隆抗体)获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2532819985","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532819985?lang=zh_cn&edition=full","pubTime":"2025-05-02 18:20","pubTimestamp":1746181219,"startTime":"0","endTime":"0","summary":"格隆汇5月2日丨石药集团公告，集团开发的重组全人源抗β Klotho单克隆抗体药物JMT202已获美国食品药品监督管理局批准，可以在美国开展临床研究。该产品亦已于2024年5月获得中国国家药品监督管理局批准，目前正在中国开展临床试验。该产品为FGFR1c/β Klotho受体激动剂，通过结合β Klotho蛋白，特异性地激活FGFR1c/β Klotho受体复合物，从而模拟其天然配体FGF21蛋白的作用，以调控糖脂代谢。本次获批的临床适应症为高甘油三酯血症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050218202494eaa6b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050218202494eaa6b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1583","LU1226287792.SGD","LU1152091168.USD","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1576","BK1521","LU0140636845.USD","03347","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0072913022.USD","BK1141","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2532868367","title":"康宁杰瑞制药-B股价涨超20% 因临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532868367","media":"iDoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532868367?lang=zh_cn&edition=full","pubTime":"2025-05-02 11:15","pubTimestamp":1746155701,"startTime":"0","endTime":"0","summary":"5月2日，康宁杰瑞制药-B股价上涨超过20%。此次上涨得益于其KN026关键性II/III期临床试验期中分析达到PFS主要终点，显示出良好的治疗潜力。这一进展有望推动公司新药研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050211153694ea6667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050211153694ea6667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1576","BK1574","BK1141","BK1161","BK1583","03347"],"gpt_icon":0},{"id":"2532508138","title":"康宁杰瑞制药-B涨超20% 因临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532508138","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532508138?lang=zh_cn&edition=full","pubTime":"2025-05-02 10:59","pubTimestamp":1746154741,"startTime":"0","endTime":"0","summary":"5月2日，康宁杰瑞制药-B股价涨超20%。据悉，其KN026关键性II/III期临床试验期中分析达到PFS主要终点，这一进展显著推动了市场对其前景的信心，从而带动股价上涨。此成果或将进一步加速该药物的研发进程。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502110032974d06b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502110032974d06b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03347","BK1141","BK1583","BK1576","09966","BK1161"],"gpt_icon":0},{"id":"2532644548","title":"开拓药业-B早盘涨近6% 脱发治疗临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532644548","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532644548?lang=zh_cn&edition=full","pubTime":"2025-05-02 10:48","pubTimestamp":1746154082,"startTime":"0","endTime":"0","summary":"5月2日，开拓药业-B（09939）早盘股价上涨5.83%，报1.27港元。公司公告显示，其KX-826与米诺地尔联合治疗男性雄激素性脱发的Ib/III期临床试验已达到主要研究终点。该试验旨在评估疗法的有效性和安全性，并为III期试验优化方案设计。基于研究成果，公司对联合疗法潜力充满信心，计划有序推进后续试验。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502105043974d0564&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502105043974d0564&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1141","BK1583","BK1515","BK1574","BK1576","03347","09939"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0959},{"period":"3month","weight":-0.0628},{"period":"6month","weight":-0.2906},{"period":"1year","weight":-0.2505},{"period":"ytd","weight":-0.1282}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1444},{"period":"3month","weight":0.0862},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.228},{"period":"ytd","weight":0.1312}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.098232},{"month":2,"riseRate":0.6,"avgChangeRate":0.033576},{"month":3,"riseRate":0.6,"avgChangeRate":-0.015339},{"month":4,"riseRate":0.2,"avgChangeRate":-0.055131},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018944},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.033557}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}